Market Access & Reimbursement
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
AstraZeneca Joins The $35 Inhaler Club; Medicare Patients Waiting On Congress For Membership
AZ’s move follows Boehringer’s announcement earlier this month and parallels what insulin sponsors did – but almost in reverse. For inhalers, political pressure on out-of-pocket costs has produced copay caps in the commercial market first, not Medicare.
Australia To Give Consumers More Formal Role In HTA Processes
The health department says consumers and patients should be able to initiate health technology assessments because many potentially helpful and lifesaving medicines might never be assessed for funding due to “a lack of commercial incentive for pharmaceutical companies.”
EC Defends Data Protection Cut As EU ‘Pharma Package’ Nears Crucial Milestone
Proposals to overhaul the general pharmaceutical legislation will ensure that the EU “continues to have one of the most generous systems of incentives in the world,” the European Commission says.
Vertex Resolves To Reverse English Funding Rejection For CRISPR Sickle Cell Gene Therapy
The health technology assessment institute, NICE, is not yet ready to recommend Casgevy for sickle cell disease and says it wants more data. Meanwhile, an access agreement relating to the treatment’s use for transfusion-dependent β-thalassemia is making progress in England, as are reimbursement talks for SCD in other European countries.
Japan Drug Price Revision: Cuts, Increases Aim To Balance National Healthcare Costs
Japan will raise reimbursement prices for selected essential and clinically valuable drugs in April, while cutting back prices for a higher than usual number of other products through the broad application of market expansion repricing rules. The overall regular revision will see prices cut by 4.7% on average.
With Reform Efforts Persisting, PBM Trade Association Sets Lobbying Record
Infographic details who gave what to whom as all segments of the US healthcare industry gear up for the presidential election cycle.
German HTA: Clinical Cancer Registries Could Hold Key To Better Comparative Data For Benefit Assessments
Better data linkage and data entry systems could transform Germany’s clinical cancer registries into a reliable data source for health technology assessments.
European Parliament Clears EU-Wide Compulsory Licensing Proposal
The draft regulation, which includes a ban on exports of drugs manufactured under an EU compulsory license, will be discussed with the EU member states after the June parliamentary elections.
Biden’s Co-Pay Cap Is Silver Lining For Pharma In Drug Pricing Campaign
President Biden’s call to expand the US Medicare price negotiation program is naturally making headlines from his campaign-year State of the Union Address. But his call for a national cap on co-pays could be an important opportunity for industry in the years to come.
Novo Nordisk’s Cardiovascular Claim For Wegovy Will Enable Medicare Coverage, CBO Assumes
Medicare has not issued a policy allowing for Part D coverage of obesity drugs with additional health claims like Wegovy’s. But expectations are growing that it will.
CSL Praises Austria’s ‘Pioneering Funding Solution’ For Gene Therapy Hemgenix
The new commercial agreement in Austria is “a strong signal” of how innovative and collaborative thinking can bring a transformative impact for patients, says CSL Behring.
EU Opens Long Awaited Consultation On Joint Clinical Assessments
Stakeholders have until 2 April to comment on the European Commission’s draft implementing act for joint clinical assessments. Industry federation EFPIA says the proposal contains numerous challenges for pharmaceutical sponsors.
Biden’s Pharma Plans Keep Industry Fighting On All Fronts
President’s State of the Union address doubled down on his desire to expand on the IRA. While the agenda poses no near-term threat, it will keep pharma on its toes as industry juggles implementation of the new Medicare prices with fighting the IRA in court and trying to reform the original law.
Who's Who In The IRA Court Drama
Pink Sheet offers a graphical guide to the lawyers behind the briefs and at the podiums for the big showdown in Trenton.
Now It’s Asthma Inhalers’ Turn: Boehringer Will Cap Copays, Cut Some List Prices As Pressure Grows
Inhalers seem poised to take insulin’s spot as a top punching bag for Rx industry critics. BI’s action, a first among the marketers of inhalers for asthma and COPD, follows challenges from Bernie Sanders and the FTC on the cost of such products.
Universal Pharmacare Makes Headway In Canada But Pharma Warns It Will Limit Access
Among the provisions in a newly tabled bill seeking to introduce a national pharmacare system in Canada is a bulk purchasing strategy for prescription drugs that could help lower costs.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.